Confirmed Speakers 2019
|
Uwe Gottschalk (Switzerland) (Chairman)
CSO - Lonza Uwe Gottschalk is Chief Technology Officer (CTO) at Lonza Pharma/Biotech since June 2014. Before joining Lonza he served as Group Vice President at Sartorius Stedim Biotech between 2004 and 2014 with a global responsibility for all bioseparation-related process technology. He worked in different capacities for Bayer Health Care from 1991 to 2004, overseeing the process development and manufacturing of biopharmaceutical products such as monoclonal antibodies and other recombinant proteins. |
|
|
Judy Chou (USA)
SVP and Global Head of Biotech - Bayer Pharmaceuticals Experienced Senior Vice President of Pharmaceutical / Technical Operations with a demonstrated history of working in the pharmaceutical industry. Skilled in Biotechnology, Drug Development & Discovery, Manufacturing& Supply Chain, Bioprocess, Analytical & Formulation, and Oncology. Strong leadership professional graduated from Yale University. |
|
|
Alain Bernard (Belgium)
Head of Biotech Process Development - R-PHARM Dr. Alain has over 30 years of experience in biotechnology process development, tech transfer, technology development and integration into process flows, including production of clinical and commercial GMP products. He previously served as Vice-President, Global Portfolio of UCB‘ s technical operations managing the prioritization and governance of the different projects. Prior to that role he was in charge of overseeing process developments for new chemical and new biological entities as well as for lifecycle management of marketed products. He joined UCB in 2006, from Serono where he was Director of Process Development. |
|
|
Kumar Dhanasekharan, Ph.D (USA)
Head of Biologics Development - Amicus Therapeutics Dr. Dhanasekharan is Head of Biologics Development at Amicus Therapeutics responsible for development and scale-up of biologics of early and late phase programs. Previously, he was responsible for process and analytical development at Cook Pharmica, a contract and development organization (CDMO) in Bloomington, Indiana. Prior to that, he was at Genzyme-Sanofi in various leadership roles including process development, process engineering and manufacturing sciences at Genzyme in Framingham, Massachusetts. |
|
|
Jens Vogel (USA)
President & CEO BI Fremont - Boehringer Ingelheim Jens H. Vogel, Ph.D. is President and CEO of Boehringer Ingelheim Fremont Inc. Jens has more than 20 years of experience in all aspects of biopharmaceutical development and manufacturing, through senior leadership roles in process & technology development, GMP manufacturing and global project leadership in the US, Germany and the UK. |
|
|
Dorothee Ambrosius (Germany)
Head of Biologicals Strategy - Boehringer Ingelheim Dorothee joined the leadership team of Boehringer Ingelheim on October 1, 2010 as Senior Vice President, Global Process Science. Her knowledge and over 20 years experience in research and development of Biopharmaceuticals has enabled her to serve as an asset to the organization as she leads the Process Science organization globally. |
|
|
Shawn Barrett (USA)
Associate Scientific Director, Continuous Manufacturing Skill Center, BioPharma Develop - Sanofi Shawn Barrett is the Associate Scientific Director of USP in the Continuous Manufacturing Skill Center at Sanofi in Framingham, MA. He has more than 20 years of experience at various organizations in the biopharmaceutical and biotech industry, including Life Technologies BioProduction, Centocor J&J R&D, Eli Lilly BioRTP, and NRC Biotechnology Research Institute. His bioprocess expertise includes fed batch and perfusion cell culture process development and scale-up, cell culture medium development, bioreactor and facility design, and process control. Shawn currently leads the optimization and intensification of a perfusion platform process for the enablement of integrated continuous manufacturing of protein therapeutics. |
|
|
April Stanley (United States)
Associate Director - Cytovance Biologics April Stanley has 15 years of industry experience. At Cytovance, she led the development of the Keystone Expression System® and development of the corresponding fed-batch platform process. She currently leads the Open Innovation group, which encompasses E. coli strain development, CHO Cell Line development, and internal R&D programs. She has a M.S. in Microbiology from the University of Illinois at Urbana-Champaign. |
|
|
Eugenio Filippi (Austria)
Head of Manufacturing Purification - Takeda Pharmaceutical Company Ltd Prior to joining Baxter as Molecular Biology Manager in 2010, Eugenio has worked in a number of roles at IBM, among which as Operations Manager in the Bratislava International Services Center in Slovakia and as IT & Transformation Manager for IBM Austria & Switzerland. Between April 2013 and June 2018 Eugenio as lead the European Plasma Operations, which include Logistics, Testing (Serological and NAT) and Plasma dispositioning. Since July 2018 he is Head of Manufacturing Purification at Shire in Vienna (now part of Takeda) Eugenio, who is originally from Italy, holds a Master of Science in Biotechnology from Wageningen University (the Netherlands) as well as a Master in Business Administration from Henley Management College (England). Aside from his interests in Cold Chain Logistics and process optimization, Eugenio has been focusing on 6 Sigma and LEAN methodologies which are becoming strong elements of his company culture. |
|
|
Christa Short (United States)
Associate Director - Upstream Christa Short has 17 years of industry experience in mammalian cell culture and bioreactor process development. She has worked with many different cell types including CHO, hybridoma, melanoma, and fibroblast developing both fed-batch and perfusion bioreactor processes at the 5L to 1000L scale. Christa has a Bachelor’s degree from the University of Oklahoma in Biochemistry. |
|
|
Zorica Dragic (Switzerland)
Team Head Cell line development - Novartis Zorica Dragic Arunasalam leads Cell Line Development team in Novartis Biologics Center, in Basel responsible for the technical development of all manufacturing cell lines for monoclonal antibodies and therapeutic proteins from early development up to and including commercial stage. Zorica graduated in Pharmacy and Medical Biochcemistry at the University of Zagreb and obtained her Ph D from the University of Basel, Switzerland. With 12 years of experience in Pharmaceutical industry, Zorica assumed different roles in biotechnology area. She led line function teams with the core expertise in the cell, process, and technology development, as well as cross functional CMC teams as technical project lead, looking into technical development and strategic aspects of early pipeline projects In her current role Zorica is leading team of motivated scientist at the interphase of discovery and development, assuring success of one of the fastest biologics pipelines in the industry. |
|
|
Stefan Schmidt (Germany)
Chief Scientific Officer - Bioatrium As CSO he is directing the department of Bioprocess Technology & Innovation focusing on identifying and implementing new manufacturing approaches and methods. He is heavily involved in the strategic orientation of our CDMO business. Prior to that as Senior Vice President Stefan managed a unit of more than 250 people performing process development and production in11 bioreactor lines with scales from 250L to 3000L both in stainless steel and disposables, delivering drug substance of complex biologics for toxicology studies, clinical trials (PI-III) and commercial supply. |
|
|
Jonathan Cartoux (France)
Field Application Engineer Life Sciences EMEA - Entegris Mr. Cartoux joined Entegris in January 2018 as an Application engineering team. He came to Entegris from Merck Millipore Sigma Company, which he joined in 2010. In his current role, Mr. Cartoux’s primary responsibilities include growing the life sciences business with his technical expertise acquired in single-use. Mr. Cartoux held Strategic Key Account manager positions at Merck Millipore Sigma Company (in France) which included; bioprocessing design engineer for single-use assemblies from upstream to final filling, E&L risk assessment and communication with a global support organization. Throughout his career Mr. Cartoux established himself as an expert in bioprocessing and single-use technologies, as recognize help for the implementation of a full single use production lines on many Sanofi sites. |
|
|
Dr. Carsten Voss (Germany)
Process Chromatography Application Manager - Bio-Rad Laboratories Dr. Carsten Voss is the Process Chromatography Applications Manager for customer support and chromatography method development at Bio-Rad Laboratories in Munich, Germany. He studied at Bielefeld University, Germany. He received his PhD at the Faculty of Technology at Bielefeld University with a thesis in fermentation engineering. He also worked as a distinguished visiting scientist at the ARC Special Research Centre for Green Chemistry at Monash University. He is an active member of several scientific organisations (ISPPP, DECHEMA, European Federation of Biotechnology) and works as a reviewer for different peer-reviewed journals as well as a lecturer in Biochemical Engineering at Bielefeld University, Germany. |
|
|
Louis Boon (Netherlands) (Chairman)
Chief Scientific Officer - Bioceros Louis Boon received his Ph.D. in Biochemistry at the University of Amsterdam. Thereafter he was one of the founders of PanGenetics and after the merger between PanGenetics and Tanox Inc. in Houston, he held a position as VP Preclinical in which he was world-wide responsible for preclinical toxicology assessments and animals studies for the Tanox group. In 2003 he was one of the founders of Bioceros BV where he currently holds a position of Chief Scientific Officer (CSO). |
|
|
Moritz von Stosch (Belgium)
Senior Manager - GSK Moritz von Stosch leads the Process Systems Biology and Engineering Center of Excellence of Technical R&D, GSK Biologicals, Belgium. He is a process systems engineer by education with a Diplom in Chemical Engineering from the RWTH- Aachen University and PhD in Biochemical Engineering from the University of Porto. Before joining GSK, Moritz worked as a Lecturer at Newcastle University, where his research focused on the development of novel hybrid modeling methods (combining fundamental knowledge and AI) and their application to enable more efficient process operation/design. |
|
|
Jan Kyhse-Andersen (Denmark)
CEO - CHRETO Dr. Jan Kyhse-Andersen is inventor of the DAP technology and founder of CHRETO. Jan has more than 25 years entrepreneurial and managerial experience from the biotechnology and diagnostic industry. Jan held a position as senior manager in Business Development at Novozymes A/S, prior to the management spin-out of the DAP technology. Jan has been supervisory Board Member in a privately equity fund, Life Equity Sweden KB for several years and prior to joining Novozymes A/S, Jan was Vice President, R&D and Production at Vir Biosensors A/S (SPR biosensor). |
|
|
Eric Abellan
Chief Technology Officer - Innovation and Analytics - Infors HT |
|
|
Lenneke de Winter (Netherlands)
Sr. Scientist USP - Bioceros Dr. de Winter received her Ph.D. in Bioprocess Engineering at Wageningen University. In 2016 she started at EPIRUS as Scientist USP. After the acquisition of Epirus NL by the Polpharma Biologics group she continued to work on biosimilar development in Bioceros and was promoted to Sr. Scientist USP. Bioceros generates production cell lines and production processes for the industry and uses its proprietary CHOBC® platform and its SPOT™ and SLIM™ technologies to generate a portfolio of cell lines producing biosimilar monoclonal antibodies. Dr. de Winter co-developed a complete process toolbox to modulate product quality to fit biosimilar CQAs |
|
|
Regina Roemling (Germany)
Marketing Manager - Tosoh Bioscience GmbH Regina Römling is Senior Marketing Manager at Tosoh Bioscience GmbH covering marketing and sales support for process chromatography media and laboratory HPLC products. She studied Chemistry at the University of Münster. Her background includes 5 years of research work in molecular biology and more than 20 years experience in liquid chromatography and mass spectrometry. |
|
|
Ralph Daumke (Switzerland)
Ralph Daumke - Filtrox Academic Studies: University of Applied Sciences Berlin, Biotechnology; ETH Zurich Department Biophysics Prof. Wüthrich; MIT Department of Biology Prof Anthony Sinskey, Degree: Diplom-Engineer in Biotechnology in 1994. Since 1996: in different positions in Sales and Marketing in different fields of Biotech and Pharma (Microscopy (Till Photonics), chromatography (PerSeptive Biosystems), DNA Microarrays (GeneScan), filtration (Amicon / Millipore). Since 2009: Sales and Marketing for FILTROX AG responsible for sales development in different markets in Europe and Asia. |
|
|
Hans J Johansson (Sweden)
Application Manager - Purolite Hans Johansson has over 30 years of experience in the biotech business, having spent 25 years with Pharmacia/Amersham/GE Healthcare. He holds more than ten patents in the area of resin design and large-scale protein purification. Hans leads the Applications group in Purolite Life Sciences - Agarose. |
|
|
John Bonham-Carter (Massachusetts)
Director - Repligen John Bonham-Carter is the Director of Upstream Sales at Repligen. John has been a serial entrepreneur with experience in multiple countries in industries from newspapers to biotechnology. Within bioprocessing, he has worked with many different upstream technologies and, most recently, has propelled the XCell™ ATF System to become the industry leader in continuous culture equipment supply. John is a regular international speaker on bioprocessing, SME entrepreneurship and business coaching. He is the editor of two eBooks: “Continuous Bioprocessing: Current Practice and Future Potential” and "Continuous Bioprocessing: Industry Best Practices". John holds a Chemistry Degree from the University of Bristol. |
|
|
Dr. Andre ten Haaf (Germany)
Scientist Custom Antibodies - Bio-Rad Laboratories I am working as a scientist for Bio-Rad since June 2016. At the Life Science Group in the department of Custom Antibodies, I am responsible for the customized antibody generation strategies and antibody characterization. Before I started at Bio-Rad, I studied bio- and nanotechnology at the University in Iserlohn (B.Sc.), molecular biotechnology at the RWTH Aachen (M.Sc.) and earned my PhD at the Justus-Liebig University in Gießen. |
|
|
Alison Arnold (United Kingdom)
Alison Arnold - Ingenza Dr. Alison Arnold is Head of Fermentation and Microbiology. She joined Ingenza in 2003 and is the longest serving member of staff. Alison has a Ph.D from University of Strathclyde in Bioscience and Biotechnology and she did her undergraduate honours degree in Chemistry at University of Aberdeen. Alison has more than 15 years experience in bioprocessing and fermentation, and has worked with a number of the big pharmaceutical companies during her Ph.D and subsequent postdoctoral research positions including Eli Lilly and DSM. The Fermentation Department is central to all of Ingenza’s business areas so Alison and her team play an integral role within the company. Alison has vast experience in developing and scaling up all of Ingenza’s fermentations from 1 to 2.6 million litres in a variety of different microorganisms. This work has taken her to many manufacturing sites in different continents around the world. She has published 15 peer-reviewed scientific articles. |
|
|
Dr Mark Lies (Germany)
Senior Global Product Manager - SCIEX Dr Mark Lies is a Global Senior product Manager for Capillary Electrophoresis (CE). Mark obtained his PhD in Molecular Genetics from the University of Kentucky in 2000. Mark has worked in the area of developing CE applications for over 14 years initially at Beckman Coulter and then with Sciex. He is currently responsible for the development and release of new CE technology at Sciex. |
|
